Literature DB >> 26500166

Addressing the stimulant treatment gap: A call to investigate the therapeutic benefits potential of cannabinoids for crack-cocaine use.

Benedikt Fischer1, Sharan Kuganesan2, Andrea Gallassi3, Renato Malcher-Lopes4, Wim van den Brink5, Evan Wood6.   

Abstract

Crack-cocaine use is prevalent in numerous countries, yet concentrated primarily - largely within urban contexts - in the Northern and Southern regions of the Americas. It is associated with a variety of behavioral, physical and mental health and social problems which gravely affect users and their environments. Few evidence-based treatments for crack-cocaine use exist and are available to users in the reality of street drug use. Numerous pharmacological treatments have been investigated but with largely disappointing results. An important therapeutic potential for crack-cocaine use may rest in cannabinoids, which have recently seen a general resurgence for varied possible therapeutic usages for different neurological diseases. Distinct potential therapeutic benefits for crack-cocaine use and common related adverse symptoms may come specifically from cannabidiol (CBD) - one of the numerous cannabinoid components found in cannabis - with its demonstrated anxiolytic, anti-psychotic, anti-convulsant effects and potential benefits for sleep and appetite problems. The possible therapeutic prospects of cannabinoids are corroborated by observational studies from different contexts documenting crack-cocaine users' 'self-medication' efforts towards coping with crack-cocaine-related problems, including withdrawal and craving, impulsivity and paranoia. Cannabinoid therapeutics offer further benefits of being available in multiple formulations, are low in adverse risk potential, and may easily be offered in community-based settings which may add to their feasibility as interventions for - predominantly marginalized - crack-cocaine user populations. Supported by the dearth of current therapeutic options for crack-cocaine use, we are advocating for the implementation of a rigorous research program investigating the potential therapeutic benefits of cannabinoids for crack-cocaine use. Given the high prevalence of this grave substance use problem in the Americas, opportunities for such research should urgently be created and facilitated there.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Americas; Cannabidiol; Cannabinoids; Crack-cocaine; Pharmacotherapy; Treatment

Mesh:

Substances:

Year:  2015        PMID: 26500166     DOI: 10.1016/j.drugpo.2015.09.005

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  15 in total

1.  The costs of crime associated with stimulant use in a Canadian setting.

Authors:  Benjamin Enns; Emanuel Krebs; Kora DeBeck; Kanna Hayashi; M-J Milloy; Lindsey Richardson; Evan Wood; Bohdan Nosyk
Journal:  Drug Alcohol Depend       Date:  2017-09-14       Impact factor: 4.492

2.  Cannabis use is associated with lower rates of initiation of injection drug use among street-involved youth: A longitudinal analysis.

Authors:  Hudson Reddon; Kora DeBeck; Maria Eugenia Socias; Huiru Dong; Evan Wood; Julio Montaner; Thomas Kerr; Michael-John Milloy
Journal:  Drug Alcohol Rev       Date:  2018-02-12

3.  Intentional cannabis use to reduce crack cocaine use in a Canadian setting: A longitudinal analysis.

Authors:  M Eugenia Socías; Thomas Kerr; Evan Wood; Huiru Dong; Stephanie Lake; Kanna Hayashi; Kora DeBeck; Didier Jutras-Aswad; Julio Montaner; M-J Milloy
Journal:  Addict Behav       Date:  2017-04-04       Impact factor: 3.913

4.  Associations of Lifetime Nonmedical Opioid, Methamphetamine, and Kratom Use within a Nationally Representative US Sample.

Authors:  Kirsten E Smith; Jeffrey M Rogers; Justin C Strickland
Journal:  J Psychoactive Drugs       Date:  2021-11-29

5.  The emergence of innovative cannabis distribution projects in the downtown eastside of Vancouver, Canada.

Authors:  Jenna Valleriani; Rebecca Haines-Saah; Rielle Capler; Ricky Bluthenthal; M Eugenia Socias; M J Milloy; Thomas Kerr; Ryan McNeil
Journal:  Int J Drug Policy       Date:  2020-04-11

6.  Ibudilast attenuates expression of behavioral sensitization to cocaine in male and female rats.

Authors:  Ryan S Poland; Yun Hahn; Pamela E Knapp; Patrick M Beardsley; M Scott Bowers
Journal:  Neuropharmacology       Date:  2016-06-22       Impact factor: 5.250

7.  Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users.

Authors:  Linwei Wang; Jeong Eun Min; Emanuel Krebs; Elizabeth Evans; David Huang; Lei Liu; Yih-Ing Hser; Bohdan Nosyk
Journal:  Int J Drug Policy       Date:  2017-09-06

8.  Cannabidiol Prevents the Expression of the Locomotor Sensitization and the Metabolic Changes in the Nucleus Accumbens and Prefrontal Cortex Elicited by the Combined Administration of Cocaine and Caffeine in Rats.

Authors:  José Pedro Prieto; Ximena López Hill; Jessika Urbanavicius; Verónica Sanchez; Xavier Nadal; Cecilia Scorza
Journal:  Neurotox Res       Date:  2020-05-15       Impact factor: 3.911

9.  Trust in research physicians as a key dimension of randomized controlled trial participation in clinical addictions research.

Authors:  Kaitlyn Jaffe; Ekaterina Nosova; Kora DeBeck; Kanna Hayashi; M-J Milloy; Lindsey Richardson
Journal:  Subst Abus       Date:  2021-03-22       Impact factor: 3.716

10.  Evaluation of Two Commercially Available Cannabidiol Formulations for Use in Electronic Cigarettes.

Authors:  Michelle R Peace; Karen E Butler; Carl E Wolf; Justin L Poklis; Alphonse Poklis
Journal:  Front Pharmacol       Date:  2016-08-29       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.